Supplemental material
Open access
3,207
Views
5
CrossRef citations to date
0
Altmetric
Oncology
Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies
Megan Pollacka Xcenda, L.L.C, Palm Harbor, FL, USACorrespondence[email protected]
, Karen Keatingb Bayer Healthcare Pharmaceuticals Inc, Whippany, NJ, USA
, Erika Wissingera Xcenda, L.L.C, Palm Harbor, FL, USA
, Louis Jacksonb Bayer Healthcare Pharmaceuticals Inc, Whippany, NJ, USA
, Evelyn Sarnesa Xcenda, L.L.C, Palm Harbor, FL, USA
& Brian Cuffelb Bayer Healthcare Pharmaceuticals Inc, Whippany, NJ, USA
Pages 59-70
|
Received 16 Sep 2020, Accepted 03 Nov 2020, Published online: 28 Nov 2020
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.